Nuvisan Pharma Services Acquires Inamed GmbH

Nuvisan Pharma Services, a CRO/CDMO group specialized in drug development services, today announces its acquisition of Inamed GmbH, an international CRO specialized in clinical trials with patients living with respiratory and rare diseases.

This acquisition gives Nuvisan access to patient populations that are very difficult to recruit, such as patients with cystic fibrosis. Inamed is also one of very few CROs in the world offering orally inhaled products flow-profile studies with a combination of all the associated skills under one roof (technical preparation of devices, flow-profile measurements, in-house clinical performance and management of some external pediatric sites).

Over the past several years, Nuvisan and Inamed have built up a close partnership through collaboration on a number of services for their customers. This new merger is the logical next step in this long lasting, successful cooperation.

The Inamed site has 28 specialist staff and is located on the periphery of Munich. It has an in-house clinical pharmacology unit of 24 beds, plus six intensive monitoring beds. The short distance to the Nuvisan headquarters ensures steady personnel exchange and just-in-time logistics between the sites.

“With Inamed’s capabilities, we are adding specialist expertise in the fields of both respiratory and combined multi-center studies. We will extend our services in patient clinical trials and increase our overnight facilities to 160 beds across the two sites,” said Dr Ralf Wulkow, executive vice president, clinical services, at Nuvisan. “The Inamed acquisition is the next step in our continuous growth strategy, which will help us become an ‘all pharma services’ company in the field of early stage drug development for the pharmaceutical industry.”

“With integration into the Nuvisan Group, we will open up the complete scope of services of a large and efficient full-service CRO for all our customers," said Dr med. Wolfgang Timmer, clinical pharmacologist and CMO at Inamed. “This also gives us a high degree of stability and the opportunity to use resources across different locations for the benefit of our customers. We anticipate that many operational synergies will emerge.”

With the new addition of Inamed services, Nuvisan now has the ability to offer a wide range of clinical trials – especially with aerosol biophysics and technology, drug discovery and life science research with desired synergistic effects – meaning all Nuvisan business units can become even more complete CRO/CDMOs.

About Inamed
Inamed was founded in 1998 as a spin-off of the GSF National Research Center for Environment and Health (now called Helmholtz Research Centre). Inamed benefits from more than 30 years of experience in aerosol biophysics and technology.

Its initial vision was to make optimized inhalation therapies a reality. Since then, the company has acquired expertise in clinical trials throughout all phases and in a wide variety of indications, far beyond respiratory.

Inamed provides its clients with a broad range of clinical trial services, ranging from Phase I trials (first-in-man trials, safety, pharmacokinetic and pharmacodynamic trials in healthy subjects or patients), Phase II-IV trials (clinical efficacy trials in patients), clinical investigations with medical devices (e.g. inhalers) and related clinical trial services, such as project management, medical writing, data management, biostatistical evaluation, quality assurance, regulatory affairs and consulting.

As an international contract research organization, Inamed provides its clients with the full range of services required for the planning, conduct and evaluation of clinical trials throughout all phases and geographical regions. For more information, visit www.inamed-cro.com.

About Nuvisan GmbH
Nuvisan Pharma Services is a 400+ employee CRO/CDMO (Contract Research Organization/Contract Development Manufacturing Organization) specialized in drug development. The company provides a wide range of services along the drug development value chain, from early hit identification to late stage clinical research with all supporting services (DMPK, GMP synthesis, formulation development and analysis, bioanalysis, Phase 1 CPU, clinical trial supplies and monitoring).

Founded in 1979 under the name LAB GmbH, its operations run at six different sites in Europe (Neu-Ulm-HQ, Berlin, Grafing, Gauting, Waltrop in Germany and Sophia-Antipolis in France) as well as monitoring units in South America. Nuvisan has achieved strong and steady growth in recent years by adding to its initial early clinical services. It currently supports the vast majority of the top pharmaceutical and early stage biotechnology companies. For more information, visit www.nuvisan.com.